Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Actionable genomic alterations in RCC

Kyrollis Attalla • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Kidney Cancer

Kyrollis Attalla, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the findings of a study describing the prevalence and landscape of actionable genomic alterations in renal cell carcinoma (RCC). Leading altered genes included TSC1 mutation, PIK3CA mutation and MET amplification. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals